BKK:TMAN-F (Thailand)
Â
Ordinary Shares (Alien Market)
฿
18.7
(0%)
Aug 13
Business Description
T.MAN Pharmaceutical PCL
Share Class Description:
BKK:TMAN-F: Ordinary Shares (Alien Market)Compare
Compare
Traded in other countries / regions
TMAN.Thailand IPO Date
2024-10-22Description
T.MAN Pharmaceutical PCL is engaged in purchasing, importing, manufacturing, and distributing original equipment and in manufacturing, distributing, and exporting modern medicines, traditional medicines, dietary supplements, and healthcare products for the healthcare industry. It offers products through brands such as T.Nutrition, T.Derma, Mommy&Me, TMT, Heaven Herb, and T.Pharmaceutical. The company's reportable segments are: Segment for manufactured products under own brand, which derives key revenue, Segment for manufactured products under third parties' brand, and Segment for trading products.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1 |
N/A
|
N/A
| |||
Equity-to-Asset | 0.58 |
N/A
|
N/A
| |||
Debt-to-Equity | 0.41 |
N/A
|
N/A
| |||
Debt-to-EBITDA | 1.2 |
N/A
|
N/A
| |||
Interest Coverage | 22.61 |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 3.29 | |||||
Beneish M-Score | -2.21 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.5 | |||||
3-Year EBITDA Growth Rate | 4 |
N/A
|
N/A
| |||
3-Year EPS without NRI Growth Rate | 0.2 |
N/A
|
N/A
| |||
3-Year FCF Growth Rate | -27.5 |
N/A
|
N/A
| |||
3-Year Book Growth Rate | 26.6 |
N/A
|
N/A
| |||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 2.86 |
N/A
|
N/A
| |||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.4 |
N/A
|
N/A
|
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.62 |
N/A
|
N/A
| |||
Quick Ratio | 1.2 |
N/A
|
N/A
| |||
Cash Ratio | 0.6 |
N/A
|
N/A
| |||
Days Inventory | 156.47 |
N/A
|
N/A
| |||
Days Sales Outstanding | 101.73 |
N/A
|
N/A
| |||
Days Payable | 125.35 |
N/A
|
N/A
|
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 46.16 |
N/A
|
N/A
| |||
Operating Margin % | 22.03 |
N/A
|
N/A
| |||
Net Margin % | 20.29 |
N/A
|
N/A
| |||
EBITDA Margin % | 30.16 |
N/A
|
N/A
| |||
FCF Margin % | 3.15 |
N/A
|
N/A
| |||
OCF Margin % | 14.86 |
N/A
|
N/A
| |||
ROE % | 25.55 |
N/A
|
N/A
| |||
ROA % | 14.03 |
N/A
|
N/A
| |||
ROIC % | 18.96 |
N/A
|
N/A
| |||
3-Year ROIIC % | 0.23 |
N/A
|
N/A
| |||
ROC (Joel Greenblatt) % | 33.64 |
N/A
|
N/A
| |||
ROCE % | 29.68 |
N/A
|
N/A
| |||
Years of Profitability over Past 10-Year | 4 |
N/A
|
N/A
|
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 8.5 |
N/A
|
N/A
| |||
Forward PE Ratio | 14.84 |
N/A
|
N/A
| |||
PE Ratio without NRI | 8.5 |
N/A
|
N/A
| |||
PS Ratio | 1.72 |
N/A
|
N/A
| |||
PB Ratio | 1.97 |
N/A
|
N/A
| |||
Price-to-Tangible-Book | 2.02 |
N/A
|
N/A
| |||
Price-to-Free-Cash-Flow | 53.14 |
N/A
|
N/A
| |||
Price-to-Operating-Cash-Flow | 11.54 |
N/A
|
N/A
| |||
EV-to-EBIT | 6.77 |
N/A
|
N/A
| |||
EV-to-EBITDA | 5.6 |
N/A
|
N/A
| |||
EV-to-Revenue | 1.68 |
N/A
|
N/A
| |||
EV-to-FCF | 55.03 |
N/A
|
N/A
| |||
Price-to-Graham-Number | 0.87 |
N/A
|
N/A
| |||
| Price-to-Net-Current-Asset-Value | 5.34 |
N/A
|
N/A
| |||
Earnings Yield (Greenblatt) % | 14.78 |
N/A
|
N/A
| |||
FCF Yield % | 1.87 |
N/A
|
N/A
|
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
T.MAN Pharmaceutical PCL Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ฿) | 2,541.74 | ||
| EPS (TTM) (฿) | 1.29 | ||
| Beta | N/A | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 2.04 | ||
| 14-Day RSI | - | ||
| 14-Day ATR (฿) | - | ||
| 20-Day SMA (฿) | 18.7 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (฿) | 18.7 - 18.7 | ||
| Shares Outstanding (Mil) | 400 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
T.MAN Pharmaceutical PCL Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
T.MAN Pharmaceutical PCL Stock Events
| Event | Date | Price (฿) | ||
|---|---|---|---|---|
| THB 0.320000 Cash Dividend | 2026-05-08 | 18.70 (+0.00%) | ||
| THB 0.240000 Cash Dividend | 2025-08-26 | 18.70 (+0.00%) | ||
| THB 0.200000 Cash Dividend | 2025-05-06 | 18.70 (+0.00%) |
Show
Entries
T.MAN Pharmaceutical PCL Frequently Asked Questions
What is T.MAN Pharmaceutical PCL(BKK:TMAN-F)'s stock price today?
The current price of BKK:TMAN-F is ฿18.70. The 52 week high of BKK:TMAN-F is ฿18.70 and 52 week low is ฿18.70.
When is next earnings date of T.MAN Pharmaceutical PCL(BKK:TMAN-F)?
The next earnings date of T.MAN Pharmaceutical PCL(BKK:TMAN-F) is .
Does T.MAN Pharmaceutical PCL(BKK:TMAN-F) pay dividends? If so, how much?
T.MAN Pharmaceutical PCL(BKK:TMAN-F) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on T.MAN Pharmaceutical PCL
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers